EGFR and non-small cell lung carcinoma: However, most of the neoadjuvant immunotherapy trials precluded EGFR/ALK mutant patients due to the inferior efficacy of immunotherapy in advanced NSCLC harboring EGFR/ALK mutation4,6,8,28.